AbbVie (NYSE: ABBV) announced positive topline results from its Phase 3 LUNA study evaluating atogepant for the preventive treatment of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE